For how we live.
A randomised trial at eight South Korean hospitals found pulse methylprednisolone no better than a non-pulse regimen for surviving an acute exacerbation of idiopathic pulmonary fibrosis.
In the DIABIL-2 trial, low-dose interleukin-2 hit its immune target in people newly diagnosed with type 1 diabetes, yet failed to preserve insulin-producing cells at one year.
Varespladib, given on top of antivenom in a randomised trial in India and the USA, did not beat placebo. But it reached patients seven hours after the bite, and the authors say that timing may be the story.
One found specific phenanthrene metabolites associated with fetal growth restriction and chased the mechanism. The other tested a 24-metabolite mixture against ADHD in 3,962 children and found nothing.
Australian teenagers harmed by the Black Summer fires showed no elevated depression, anxiety, distress, insomnia or suicidality two years later. The result runs against a systematic review published months earlier.